Research ExplorerPublicationsAchievement of complete remission predicts outcome of alloge...

Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation

Standard

Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. / Symeonidis, Argiris; van Biezen, Anja; de Wreede, Liesbeth; Piciocchi, Alfonso; Finke, Juergen; Beelen, Dietrich; Bornhäuser, Martin; Cornelissen, Jan; Volin, Liisa; Mufti, Ghulam; Chalandon, Yves; Ganser, Arnold; Bruno, Benedetto; Niederwieser, Dietger; Kobbe, Guido; Schwerdtfeger, Rainer; de Witte, Theo; Robin, Marie; Kröger, Nicolaus; Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT).

In: BRIT J HAEMATOL, Vol. 171, No. 2, 10.2015, p. 239-246.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Symeonidis, A, van Biezen, A, de Wreede, L, Piciocchi, A, Finke, J, Beelen, D, Bornhäuser, M, Cornelissen, J, Volin, L, Mufti, G, Chalandon, Y, Ganser, A, Bruno, B, Niederwieser, D, Kobbe, G, Schwerdtfeger, R, de Witte, T, Robin, M, Kröger, N & Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT) 2015, 'Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation', BRIT J HAEMATOL, vol. 171, no. 2, pp. 239-246. https://doi.org/10.1111/bjh.13576

APA

Symeonidis, A., van Biezen, A., de Wreede, L., Piciocchi, A., Finke, J., Beelen, D., Bornhäuser, M., Cornelissen, J., Volin, L., Mufti, G., Chalandon, Y., Ganser, A., Bruno, B., Niederwieser, D., Kobbe, G., Schwerdtfeger, R., de Witte, T., Robin, M., Kröger, N., & Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT) (2015). Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. BRIT J HAEMATOL, 171(2), 239-246. https://doi.org/10.1111/bjh.13576

Vancouver

Symeonidis A, van Biezen A, de Wreede L, Piciocchi A, Finke J, Beelen D et al. Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. BRIT J HAEMATOL. 2015 Oct;171(2):239-246. https://doi.org/10.1111/bjh.13576

Bibtex

@article{f8d1e92a19674b32a74ccab336fcd949,
title = "Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation",
abstract = "The results of allogeneic stem cell transplantation (allo-SCT) in chronic myelomonocytic leukaemia (CMML) are usually reported together with other categories of myelodysplastic syndrome. We analysed transplantation outcome in 513 patients with CMML, with a median age of 53 years reported to the European Group for Blood and Marrow Transplantation. Conditioning was standard (n = 249) or reduced-intensity (n = 226). Donors were human leucocyte antigen-related (n = 285) or unrelated (n = 228). Disease status at transplantation was complete remission (CR) in 122 patients, no CR in 344, and unknown in 47. Engraftment was successful in 95%. Grades 2-4 acute graft-versus-host disease (GvHD) occurred in 33% of the patients and chronic GvHD was reported in 24%. The 4-year cumulative incidence of non-relapse mortality was 41% and 32% for relapse, resulting in a 4-year estimated relapse-free and overall survival (OS) of 27% and 33%, respectively. Patients transplanted in CR had lower probability for non-relapse death (P = 0·002) and longer relapse-free and OS (P = 0·001 and P = 0·005, respectively). In multivariate analysis the only significant prognostic factor for survival was the presence of CR at transplantation (P = 0·005). Allo-SCT remains a curative treatment option for patients with CMML and should preferably be performed early after diagnosis or after establishing the best possible remission status.",
keywords = "Journal Article",
author = "Argiris Symeonidis and {van Biezen}, Anja and {de Wreede}, Liesbeth and Alfonso Piciocchi and Juergen Finke and Dietrich Beelen and Martin Bornh{\"a}user and Jan Cornelissen and Liisa Volin and Ghulam Mufti and Yves Chalandon and Arnold Ganser and Benedetto Bruno and Dietger Niederwieser and Guido Kobbe and Rainer Schwerdtfeger and {de Witte}, Theo and Marie Robin and Nicolaus Kr{\"o}ger and {Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT)}",
note = "{\textcopyright} 2015 John Wiley & Sons Ltd.",
year = "2015",
month = oct,
doi = "10.1111/bjh.13576",
language = "English",
volume = "171",
pages = "239--246",
journal = "BRIT J HAEMATOL",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "2",

}

RIS

TY - JOUR

T1 - Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation

AU - Symeonidis, Argiris

AU - van Biezen, Anja

AU - de Wreede, Liesbeth

AU - Piciocchi, Alfonso

AU - Finke, Juergen

AU - Beelen, Dietrich

AU - Bornhäuser, Martin

AU - Cornelissen, Jan

AU - Volin, Liisa

AU - Mufti, Ghulam

AU - Chalandon, Yves

AU - Ganser, Arnold

AU - Bruno, Benedetto

AU - Niederwieser, Dietger

AU - Kobbe, Guido

AU - Schwerdtfeger, Rainer

AU - de Witte, Theo

AU - Robin, Marie

AU - Kröger, Nicolaus

AU - Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

N1 - © 2015 John Wiley & Sons Ltd.

PY - 2015/10

Y1 - 2015/10

N2 - The results of allogeneic stem cell transplantation (allo-SCT) in chronic myelomonocytic leukaemia (CMML) are usually reported together with other categories of myelodysplastic syndrome. We analysed transplantation outcome in 513 patients with CMML, with a median age of 53 years reported to the European Group for Blood and Marrow Transplantation. Conditioning was standard (n = 249) or reduced-intensity (n = 226). Donors were human leucocyte antigen-related (n = 285) or unrelated (n = 228). Disease status at transplantation was complete remission (CR) in 122 patients, no CR in 344, and unknown in 47. Engraftment was successful in 95%. Grades 2-4 acute graft-versus-host disease (GvHD) occurred in 33% of the patients and chronic GvHD was reported in 24%. The 4-year cumulative incidence of non-relapse mortality was 41% and 32% for relapse, resulting in a 4-year estimated relapse-free and overall survival (OS) of 27% and 33%, respectively. Patients transplanted in CR had lower probability for non-relapse death (P = 0·002) and longer relapse-free and OS (P = 0·001 and P = 0·005, respectively). In multivariate analysis the only significant prognostic factor for survival was the presence of CR at transplantation (P = 0·005). Allo-SCT remains a curative treatment option for patients with CMML and should preferably be performed early after diagnosis or after establishing the best possible remission status.

AB - The results of allogeneic stem cell transplantation (allo-SCT) in chronic myelomonocytic leukaemia (CMML) are usually reported together with other categories of myelodysplastic syndrome. We analysed transplantation outcome in 513 patients with CMML, with a median age of 53 years reported to the European Group for Blood and Marrow Transplantation. Conditioning was standard (n = 249) or reduced-intensity (n = 226). Donors were human leucocyte antigen-related (n = 285) or unrelated (n = 228). Disease status at transplantation was complete remission (CR) in 122 patients, no CR in 344, and unknown in 47. Engraftment was successful in 95%. Grades 2-4 acute graft-versus-host disease (GvHD) occurred in 33% of the patients and chronic GvHD was reported in 24%. The 4-year cumulative incidence of non-relapse mortality was 41% and 32% for relapse, resulting in a 4-year estimated relapse-free and overall survival (OS) of 27% and 33%, respectively. Patients transplanted in CR had lower probability for non-relapse death (P = 0·002) and longer relapse-free and OS (P = 0·001 and P = 0·005, respectively). In multivariate analysis the only significant prognostic factor for survival was the presence of CR at transplantation (P = 0·005). Allo-SCT remains a curative treatment option for patients with CMML and should preferably be performed early after diagnosis or after establishing the best possible remission status.

KW - Journal Article

U2 - 10.1111/bjh.13576

DO - 10.1111/bjh.13576

M3 - SCORING: Journal article

C2 - 26212516

VL - 171

SP - 239

EP - 246

JO - BRIT J HAEMATOL

JF - BRIT J HAEMATOL

SN - 0007-1048

IS - 2

ER -